Tags

Type your tag names separated by a space and hit enter

Histone Methylation Regulation in Neurodegenerative Disorders.
Int J Mol Sci. 2021 Apr 28; 22(9)IJ

Abstract

Advances achieved with molecular biology and genomics technologies have permitted investigators to discover epigenetic mechanisms, such as DNA methylation and histone posttranslational modifications, which are critical for gene expression in almost all tissues and in brain health and disease. These advances have influenced much interest in understanding the dysregulation of epigenetic mechanisms in neurodegenerative disorders. Although these disorders diverge in their fundamental causes and pathophysiology, several involve the dysregulation of histone methylation-mediated gene expression. Interestingly, epigenetic remodeling via histone methylation in specific brain regions has been suggested to play a critical function in the neurobiology of psychiatric disorders, including that related to neurodegenerative diseases. Prominently, epigenetic dysregulation currently brings considerable interest as an essential player in neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic lateral sclerosis (ALS) and drugs of abuse, including alcohol abuse disorder, where it may facilitate connections between genetic and environmental risk factors or directly influence disease-specific pathological factors. We have discussed the current state of histone methylation, therapeutic strategies, and future perspectives for these disorders. While not somatically heritable, the enzymes responsible for histone methylation regulation, such as histone methyltransferases and demethylases in neurons, are dynamic and reversible. They have become promising potential therapeutic targets to treat or prevent several neurodegenerative disorders. These findings, along with clinical data, may provide links between molecular-level changes and behavioral differences and provide novel avenues through which the epigenome may be targeted early on in people at risk for neurodegenerative disorders.

Authors+Show Affiliations

Division of Analytical Psychopharmacology, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA. New York State Psychiatric Institute, New York, NY 10032, USA. Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA. New York University Langone Medical Center, Department of Psychiatry, New York, NY 10016, USA.Division of Analytical Psychopharmacology, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33925016

Citation

Basavarajappa, Balapal S., and Shivakumar Subbanna. "Histone Methylation Regulation in Neurodegenerative Disorders." International Journal of Molecular Sciences, vol. 22, no. 9, 2021.
Basavarajappa BS, Subbanna S. Histone Methylation Regulation in Neurodegenerative Disorders. Int J Mol Sci. 2021;22(9).
Basavarajappa, B. S., & Subbanna, S. (2021). Histone Methylation Regulation in Neurodegenerative Disorders. International Journal of Molecular Sciences, 22(9). https://doi.org/10.3390/ijms22094654
Basavarajappa BS, Subbanna S. Histone Methylation Regulation in Neurodegenerative Disorders. Int J Mol Sci. 2021 Apr 28;22(9) PubMed PMID: 33925016.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Histone Methylation Regulation in Neurodegenerative Disorders. AU - Basavarajappa,Balapal S, AU - Subbanna,Shivakumar, Y1 - 2021/04/28/ PY - 2021/03/26/received PY - 2021/04/21/revised PY - 2021/04/23/accepted PY - 2021/4/30/entrez PY - 2021/5/1/pubmed PY - 2021/5/25/medline KW - Alzheimer’s disease KW - Amyotrophic lateral sclerosis KW - Huntington’s disease KW - Parkinson’s disease KW - epigenetics KW - neuronal loss and alcohol JF - International journal of molecular sciences JO - Int J Mol Sci VL - 22 IS - 9 N2 - Advances achieved with molecular biology and genomics technologies have permitted investigators to discover epigenetic mechanisms, such as DNA methylation and histone posttranslational modifications, which are critical for gene expression in almost all tissues and in brain health and disease. These advances have influenced much interest in understanding the dysregulation of epigenetic mechanisms in neurodegenerative disorders. Although these disorders diverge in their fundamental causes and pathophysiology, several involve the dysregulation of histone methylation-mediated gene expression. Interestingly, epigenetic remodeling via histone methylation in specific brain regions has been suggested to play a critical function in the neurobiology of psychiatric disorders, including that related to neurodegenerative diseases. Prominently, epigenetic dysregulation currently brings considerable interest as an essential player in neurodegenerative disorders, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic lateral sclerosis (ALS) and drugs of abuse, including alcohol abuse disorder, where it may facilitate connections between genetic and environmental risk factors or directly influence disease-specific pathological factors. We have discussed the current state of histone methylation, therapeutic strategies, and future perspectives for these disorders. While not somatically heritable, the enzymes responsible for histone methylation regulation, such as histone methyltransferases and demethylases in neurons, are dynamic and reversible. They have become promising potential therapeutic targets to treat or prevent several neurodegenerative disorders. These findings, along with clinical data, may provide links between molecular-level changes and behavioral differences and provide novel avenues through which the epigenome may be targeted early on in people at risk for neurodegenerative disorders. SN - 1422-0067 UR - https://www.unboundmedicine.com/medline/citation/33925016/Histone_Methylation_Regulation_in_Neurodegenerative_Disorders_ DB - PRIME DP - Unbound Medicine ER -